Corindus Adds Two New CorPath GRX Installations to HCA Healthcare Facilities
18 Juli 2019 - 12:45PM
Business Wire
One of the nation’s largest hospital networks
adopts vascular robotic technology in multiple hospital locations
to treat patients in need of cardiovascular care
Corindus Vascular Robotics, Inc. (“Corindus” or the
“Company”) (NYSE American: CVRS), a leading developer of precision
vascular robotics, announced today that it has installed CorPath®
GRX Systems in two new hospitals affiliated with one of the
nation’s largest hospital networks, HCA Healthcare.
The new systems are now installed in hospital locations in Florida
and Texas, bringing the total number of HCA hospitals utilizing
CorPath GRX to three.
“We are pleased with HCA Healthcare’s continued commitment to
our CorPath GRX technology and the work we are doing to bring
next-generation robotic solutions to the cath lab. This expansion
further validates HCA’s interest in adopting next-generation
solutions to improve patient care and outcomes, while offering
their providers state-of-the art tools to do so,” said Mark Toland,
President and Chief Executive Officer of Corindus. “Having renowned
hospital networks, such as HCA Healthcare, adopt robotics and offer
patients advanced treatment options, serves as a key driver in our
goal to expand robotic-assisted procedures to other areas of care
in need of the technology.”
Based in Nashville, Tenn., HCA Healthcare is one of the nation's
leading providers of healthcare services. It has 185 hospitals and
approximately 2,000 sites of care located across 21 states and the
United Kingdom. Its facilities include surgery centers,
freestanding ERs, urgent care centers, and physician clinics.
To learn more about Corindus and CorPath GRX, please visit
www.corindus.com.
About Corindus Vascular Robotics, Inc.
Corindus Vascular Robotics is a global technology leader in
robotic-assisted vascular interventions. The Company’s CorPath®
platform is the first FDA-cleared medical device to bring robotic
precision to percutaneous coronary and vascular procedures. CorPath
GRX is the second generation robotic-assisted technology offering
enhancements to the platform by adding important key upgrades that
increase precision, improve workflow, and extend the capabilities
and range of procedures that can be performed robotically. We are
focused on developing innovative robotic solutions to revolutionize
treatment of emergent conditions by providing specialized and
timely medical care to patients around the world. For additional
information, visit www.corindus.com, and follow
@CorindusInc.
About HCA Healthcare
Nashville-based HCA Healthcare is one of the nation's leading
providers of healthcare services, comprising 185 hospitals and
approximately 2,000 sites of care, including surgery centers,
freestanding ERs, urgent care centers, and physician clinics, in 21
states and the United Kingdom. With its founding in 1968, HCA
Healthcare created a new model for hospital care in the United
States, using combined resources to strengthen hospitals, deliver
patient-focused care and improve the practice of medicine. HCA
Healthcare has conducted a number of clinical studies, including
one that demonstrated that full-term delivery is healthier than
early elective delivery of babies and another that identified a
clinical protocol that can reduce bloodstream infections in ICU
patients by 44 percent. HCA Healthcare is a learning healthcare
system that uses its more than 31 million annual patient encounters
to advance science, improve patient care and save lives.
Forward Looking Statements
Statements made in this release that are not statements of
historical or current facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements may involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, performance or achievements of Corindus to be materially
different from historical results or from any future results or
projections expressed or implied by such forward-looking
statements. Accordingly, readers should not place undue reliance on
any forward-looking statements. In addition to statements that
explicitly describe such risks and uncertainties, readers are urged
to consider statements in the conditional or future tenses or that
includes terms such as "believes," "belief," "expects,"
"estimates," "intends," "anticipates" or "plans" to be uncertain
and forward-looking. Forward-looking statements may include
comments as to Corindus’ beliefs and expectations as to future
events and trends affecting its business and are necessarily
subject to uncertainties, many of which are outside Corindus’
control.
Examples of such statements include statements regarding or such
as:
- HCA’s interest in adopting next-generation solutions to improve
patient care and outcomes; and
- The expansion of robotic-assisted procedures to areas of care
other than cardiovascular care.
Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements
are described in the sections titled "Risk Factors" in the
Company's filings with the Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as reports on Form 8-K, including,
but not limited to the following: our ability to expand our
technology platform and achieve the advances necessary for
telestenting and remote procedures, including in humans; our
ability to expand our technology platform for use in other segments
of the vascular intervention market, including neurointerventional
and other more complex cardiac interventions; obtaining necessary
regulatory approvals for the use on humans and marketing of our
products in the United States and in other countries, including for
stroke and other neurovascular interventions; the rate of adoption
of our CorPath System and the rate of use of our cassettes; risks
associated with market acceptance, including pricing and
reimbursement; our ability to enforce our intellectual property
rights; our need for additional funds to support our operations;
our ability to manage expenses and cash flow; factors relating to
engineering, regulatory, manufacturing, sales and customer service
challenges; potential safety and regulatory issues that could slow
or suspend our sales; and the effect of credit, financial and
economic conditions on capital spending by our potential customers.
Forward looking statements speak only as of the date they are made.
Corindus undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise that occur after that date. More
information is available on Corindus' website at
http://www.corindus.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190718005211/en/
Media Contact: Matter for Corindus Jessica Wolter 617-391-9896
corindus@matternow.com
Investor Contact: In-Site Communications, Inc. Lisa Wilson T:
917-543-9932 ir@corindus.com
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
Von Dez 2023 bis Dez 2024